Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Placenta Accreta | 22 | 2026 | 177 | 13.120 |
Why?
|
| Hysterectomy | 16 | 2025 | 205 | 6.210 |
Why?
|
| Cesarean Section | 16 | 2026 | 436 | 5.270 |
Why?
|
| Pregnancy | 45 | 2026 | 7572 | 2.640 |
Why?
|
| Fetal Diseases | 6 | 2025 | 460 | 2.630 |
Why?
|
| Perinatal Death | 3 | 2023 | 28 | 1.770 |
Why?
|
| Fetofetal Transfusion | 4 | 2025 | 198 | 1.700 |
Why?
|
| Meningomyelocele | 4 | 2026 | 272 | 1.540 |
Why?
|
| Fetoscopy | 4 | 2025 | 462 | 1.490 |
Why?
|
| Retrospective Studies | 33 | 2026 | 17667 | 1.370 |
Why?
|
| Intensive Care Units | 2 | 2025 | 517 | 1.370 |
Why?
|
| Postpartum Hemorrhage | 5 | 2026 | 118 | 1.330 |
Why?
|
| Dacarbazine | 3 | 2015 | 93 | 1.310 |
Why?
|
| Pregnancy, Twin | 4 | 2025 | 192 | 1.240 |
Why?
|
| Case-Control Studies | 12 | 2026 | 3454 | 1.210 |
Why?
|
| Placenta | 9 | 2025 | 529 | 1.150 |
Why?
|
| Apgar Score | 2 | 2025 | 50 | 1.130 |
Why?
|
| Fetal Therapies | 2 | 2025 | 85 | 1.100 |
Why?
|
| Female | 50 | 2026 | 71185 | 1.070 |
Why?
|
| Patient Admission | 2 | 2025 | 184 | 1.050 |
Why?
|
| Blood Loss, Surgical | 2 | 2025 | 169 | 1.040 |
Why?
|
| Ultrasonography, Prenatal | 7 | 2026 | 1006 | 1.020 |
Why?
|
| Oligohydramnios | 2 | 2025 | 48 | 1.020 |
Why?
|
| Uterine Hemorrhage | 2 | 2024 | 42 | 1.020 |
Why?
|
| Infant, Newborn | 17 | 2025 | 8589 | 0.980 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2015 | 98 | 0.960 |
Why?
|
| Watchful Waiting | 2 | 2025 | 74 | 0.890 |
Why?
|
| Balloon Occlusion | 1 | 2025 | 48 | 0.880 |
Why?
|
| Placenta Previa | 2 | 2022 | 66 | 0.880 |
Why?
|
| Conservative Treatment | 1 | 2025 | 42 | 0.870 |
Why?
|
| Blood Transfusion | 5 | 2025 | 290 | 0.860 |
Why?
|
| Blood Transfusion, Intrauterine | 1 | 2024 | 36 | 0.860 |
Why?
|
| Fetal Growth Retardation | 3 | 2025 | 259 | 0.860 |
Why?
|
| Amniotic Fluid | 3 | 2025 | 149 | 0.820 |
Why?
|
| Fetal Heart | 1 | 2025 | 135 | 0.820 |
Why?
|
| Uterine Artery Embolization | 1 | 2023 | 4 | 0.800 |
Why?
|
| Humans | 57 | 2026 | 131679 | 0.800 |
Why?
|
| Urinary Tract | 1 | 2023 | 61 | 0.790 |
Why?
|
| Laser Coagulation | 1 | 2024 | 109 | 0.790 |
Why?
|
| Pregnancy Outcome | 7 | 2025 | 630 | 0.780 |
Why?
|
| Glioblastoma | 3 | 2015 | 346 | 0.760 |
Why?
|
| Tranexamic Acid | 1 | 2023 | 31 | 0.760 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2022 | 77 | 0.730 |
Why?
|
| Oncologists | 1 | 2022 | 31 | 0.730 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1139 | 0.670 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2025 | 3917 | 0.670 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2015 | 825 | 0.650 |
Why?
|
| Prenatal Diagnosis | 7 | 2025 | 653 | 0.640 |
Why?
|
| Adult | 22 | 2026 | 31719 | 0.640 |
Why?
|
| Goiter | 2 | 2019 | 8 | 0.620 |
Why?
|
| Propylthiouracil | 2 | 2019 | 9 | 0.620 |
Why?
|
| Premature Birth | 2 | 2023 | 415 | 0.610 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2019 | 42 | 0.600 |
Why?
|
| Thyroxine | 2 | 2019 | 62 | 0.600 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 29 | 0.580 |
Why?
|
| Spine | 1 | 2019 | 148 | 0.580 |
Why?
|
| Vulvovaginitis | 1 | 2017 | 2 | 0.520 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 316 | 0.500 |
Why?
|
| Symptom Assessment | 1 | 2017 | 110 | 0.500 |
Why?
|
| Mental Disorders | 1 | 2024 | 904 | 0.490 |
Why?
|
| Twins, Monozygotic | 3 | 2025 | 125 | 0.480 |
Why?
|
| Prenatal Injuries | 1 | 2015 | 2 | 0.470 |
Why?
|
| Thyroid Hormones | 1 | 2015 | 56 | 0.450 |
Why?
|
| Bone Marrow Cells | 2 | 2015 | 244 | 0.440 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 203 | 0.410 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 432 | 0.380 |
Why?
|
| Polycythemia | 2 | 2024 | 45 | 0.370 |
Why?
|
| Insurance Coverage | 2 | 2023 | 117 | 0.370 |
Why?
|
| Anesthesia, General | 2 | 2022 | 128 | 0.340 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12984 | 0.330 |
Why?
|
| Neurogenesis | 1 | 2012 | 224 | 0.320 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 2 | 2025 | 432 | 0.320 |
Why?
|
| Length of Stay | 2 | 2025 | 1399 | 0.300 |
Why?
|
| Brain Neoplasms | 2 | 2015 | 1298 | 0.290 |
Why?
|
| Predictive Value of Tests | 4 | 2026 | 2297 | 0.270 |
Why?
|
| MicroRNAs | 1 | 2015 | 894 | 0.270 |
Why?
|
| Hyperthyroidism | 2 | 2019 | 24 | 0.260 |
Why?
|
| Vein of Galen Malformations | 1 | 2025 | 15 | 0.240 |
Why?
|
| Insurance, Health | 2 | 2023 | 140 | 0.230 |
Why?
|
| Pulmonary Edema | 1 | 2025 | 57 | 0.230 |
Why?
|
| Encephalocele | 1 | 2025 | 65 | 0.220 |
Why?
|
| Hydrops Fetalis | 1 | 2025 | 84 | 0.220 |
Why?
|
| Rhombencephalon | 1 | 2025 | 68 | 0.220 |
Why?
|
| Neurons | 2 | 2012 | 1990 | 0.220 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 59 | 0.220 |
Why?
|
| Polyhydramnios | 1 | 2025 | 54 | 0.220 |
Why?
|
| Rh Isoimmunization | 1 | 2024 | 27 | 0.220 |
Why?
|
| Parvoviridae Infections | 1 | 2024 | 34 | 0.220 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2026 | 182 | 0.220 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2025 | 167 | 0.220 |
Why?
|
| Spinal Cord | 1 | 2026 | 269 | 0.210 |
Why?
|
| Operative Time | 1 | 2025 | 205 | 0.210 |
Why?
|
| Transfection | 3 | 2015 | 960 | 0.210 |
Why?
|
| Sutures | 1 | 2024 | 65 | 0.210 |
Why?
|
| Pleural Effusion | 1 | 2024 | 106 | 0.200 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 3673 | 0.190 |
Why?
|
| Uterine Artery | 1 | 2023 | 27 | 0.190 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2025 | 342 | 0.190 |
Why?
|
| Depression, Postpartum | 1 | 2023 | 51 | 0.190 |
Why?
|
| Gestational Age | 3 | 2025 | 1221 | 0.190 |
Why?
|
| Phenotype | 1 | 2012 | 4516 | 0.190 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 225 | 0.190 |
Why?
|
| Child Development | 1 | 2025 | 272 | 0.180 |
Why?
|
| Risk Factors | 4 | 2024 | 10959 | 0.180 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2023 | 69 | 0.180 |
Why?
|
| Machine Learning | 1 | 2026 | 375 | 0.180 |
Why?
|
| Spinal Dysraphism | 1 | 2025 | 279 | 0.180 |
Why?
|
| Neural Tube Defects | 1 | 2025 | 380 | 0.180 |
Why?
|
| Jaundice, Neonatal | 1 | 2021 | 10 | 0.180 |
Why?
|
| Rural Population | 1 | 2023 | 260 | 0.170 |
Why?
|
| Obstetrics | 1 | 2023 | 246 | 0.170 |
Why?
|
| Laser Therapy | 1 | 2023 | 239 | 0.160 |
Why?
|
| Mental Health | 1 | 2024 | 383 | 0.160 |
Why?
|
| Medicaid | 1 | 2023 | 252 | 0.160 |
Why?
|
| Hypoglycemia | 1 | 2021 | 181 | 0.160 |
Why?
|
| Diabetes, Gestational | 1 | 2021 | 111 | 0.150 |
Why?
|
| Consensus | 1 | 2022 | 565 | 0.150 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2024 | 500 | 0.150 |
Why?
|
| Antithyroid Agents | 1 | 2019 | 4 | 0.150 |
Why?
|
| Echocardiography | 1 | 2025 | 1138 | 0.150 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2011 | 81 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2025 | 611 | 0.140 |
Why?
|
| Signal Transduction | 4 | 2015 | 4683 | 0.140 |
Why?
|
| Pregnancy Complications | 2 | 2023 | 547 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2019 | 78 | 0.140 |
Why?
|
| United States | 3 | 2023 | 11804 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 1989 | 0.130 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2017 | 3 | 0.130 |
Why?
|
| Trichomonas Vaginitis | 1 | 2017 | 14 | 0.130 |
Why?
|
| Vaginosis, Bacterial | 1 | 2017 | 18 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 2989 | 0.130 |
Why?
|
| Herpes Genitalis | 1 | 2017 | 10 | 0.130 |
Why?
|
| Lichen Planus | 1 | 2017 | 9 | 0.130 |
Why?
|
| Infant, Premature | 1 | 2022 | 856 | 0.130 |
Why?
|
| Neonatal Screening | 1 | 2019 | 195 | 0.130 |
Why?
|
| Lung | 1 | 2025 | 1565 | 0.130 |
Why?
|
| Hypertension | 1 | 2025 | 1360 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 697 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1454 | 0.130 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2015 | 23 | 0.120 |
Why?
|
| Fluoresceins | 1 | 2015 | 31 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2015 | 1018 | 0.120 |
Why?
|
| Binding, Competitive | 1 | 2015 | 152 | 0.120 |
Why?
|
| Infant | 3 | 2026 | 13306 | 0.110 |
Why?
|
| Caspase 3 | 1 | 2015 | 127 | 0.110 |
Why?
|
| Patched Receptors | 1 | 2015 | 27 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 1236 | 0.110 |
Why?
|
| Cricetinae | 1 | 2015 | 367 | 0.110 |
Why?
|
| Animals | 7 | 2015 | 34375 | 0.110 |
Why?
|
| Patched-1 Receptor | 1 | 2015 | 38 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 270 | 0.110 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 164 | 0.110 |
Why?
|
| Hysterotomy | 2 | 2025 | 135 | 0.110 |
Why?
|
| Cells, Cultured | 4 | 2012 | 2971 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 1122 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 414 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 191 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2025 | 3130 | 0.100 |
Why?
|
| RNA Interference | 1 | 2015 | 496 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 329 | 0.100 |
Why?
|
| Connexin 43 | 1 | 2012 | 35 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 36 | 0.100 |
Why?
|
| Gap Junctions | 1 | 2012 | 44 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2015 | 832 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2014 | 296 | 0.100 |
Why?
|
| Protein Kinase C | 1 | 2012 | 114 | 0.090 |
Why?
|
| Cats | 1 | 2012 | 121 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2015 | 810 | 0.090 |
Why?
|
| Antigens, Surface | 1 | 2012 | 116 | 0.090 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2012 | 102 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 1021 | 0.090 |
Why?
|
| Tachykinins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Adipogenesis | 1 | 2012 | 80 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1626 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 2648 | 0.090 |
Why?
|
| Species Specificity | 1 | 2012 | 519 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1911 | 0.090 |
Why?
|
| Osteogenesis | 1 | 2012 | 167 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 1001 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 704 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 677 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 1397 | 0.080 |
Why?
|
| Repressor Proteins | 2 | 2011 | 777 | 0.080 |
Why?
|
| Male | 5 | 2026 | 65266 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2463 | 0.070 |
Why?
|
| Transplantation Tolerance | 1 | 2008 | 11 | 0.070 |
Why?
|
| Spinal Cord Injuries | 1 | 2011 | 278 | 0.070 |
Why?
|
| Cell Transdifferentiation | 1 | 2008 | 58 | 0.070 |
Why?
|
| Immune Tolerance | 1 | 2008 | 159 | 0.060 |
Why?
|
| Dopamine | 1 | 2008 | 256 | 0.060 |
Why?
|
| Mean Platelet Volume | 1 | 2026 | 11 | 0.060 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2025 | 50 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2026 | 126 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 2357 | 0.060 |
Why?
|
| Regeneration | 1 | 2008 | 231 | 0.060 |
Why?
|
| Lung Volume Measurements | 1 | 2025 | 84 | 0.050 |
Why?
|
| Edema | 1 | 2025 | 139 | 0.050 |
Why?
|
| Tensile Strength | 1 | 2024 | 46 | 0.050 |
Why?
|
| Polyesters | 1 | 2024 | 35 | 0.050 |
Why?
|
| Materials Testing | 1 | 2024 | 80 | 0.050 |
Why?
|
| Organ Size | 1 | 2025 | 435 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2008 | 1947 | 0.050 |
Why?
|
| Parity | 1 | 2023 | 84 | 0.050 |
Why?
|
| Cell Communication | 2 | 2015 | 196 | 0.050 |
Why?
|
| Hydrocephalus | 1 | 2025 | 292 | 0.050 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2023 | 76 | 0.050 |
Why?
|
| Fetal Death | 1 | 2023 | 119 | 0.050 |
Why?
|
| Syndrome | 1 | 2025 | 1168 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2023 | 251 | 0.050 |
Why?
|
| Constriction | 1 | 2021 | 47 | 0.040 |
Why?
|
| Umbilical Cord | 1 | 2021 | 61 | 0.040 |
Why?
|
| Bilirubin | 1 | 2021 | 126 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2023 | 1405 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 1958 | 0.040 |
Why?
|
| Young Adult | 3 | 2023 | 10104 | 0.040 |
Why?
|
| Co-Repressor Proteins | 2 | 2011 | 38 | 0.040 |
Why?
|
| Mice | 2 | 2014 | 18488 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2024 | 1099 | 0.030 |
Why?
|
| Ohio | 1 | 2017 | 88 | 0.030 |
Why?
|
| Mass Screening | 1 | 2023 | 825 | 0.030 |
Why?
|
| Anxiety | 1 | 2023 | 1028 | 0.030 |
Why?
|
| Biomarkers | 1 | 2026 | 3405 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 6279 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5123 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2568 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 140 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 1350 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 854 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3834 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 6494 | 0.020 |
Why?
|
| Cellular Microenvironment | 1 | 2011 | 16 | 0.020 |
Why?
|
| Activating Transcription Factors | 1 | 2011 | 3 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2011 | 35 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 51 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 98 | 0.020 |
Why?
|
| Response Elements | 1 | 2011 | 99 | 0.020 |
Why?
|
| Tretinoin | 1 | 2011 | 97 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2011 | 112 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 261 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 530 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 350 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 226 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2026 | 15057 | 0.020 |
Why?
|
| Incidence | 1 | 2017 | 3347 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1571 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2008 | 34 | 0.020 |
Why?
|
| Biophysical Phenomena | 1 | 2008 | 40 | 0.020 |
Why?
|
| Binding Sites | 1 | 2011 | 1202 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2008 | 47 | 0.020 |
Why?
|
| Zebrafish | 1 | 2011 | 428 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2008 | 27 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 62 | 0.020 |
Why?
|
| Sodium Channels | 1 | 2008 | 99 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2008 | 279 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 476 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2008 | 55 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2008 | 297 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1712 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2008 | 78 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 279 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 293 | 0.020 |
Why?
|
| Immunization | 1 | 2008 | 307 | 0.020 |
Why?
|
| Adolescent | 2 | 2017 | 20982 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1392 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 665 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1810 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 568 | 0.010 |
Why?
|
| Child | 1 | 2023 | 26299 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2008 | 2437 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 28888 | 0.010 |
Why?
|
| Neoplasms | 1 | 2008 | 2969 | 0.010 |
Why?
|